Search

Displaying results 111 - 120 of 179 in total
  1. Pathway

    Tyrosinemia, Transient, of the Newborn

    smpdb.ca/view/SMP0000494
    Disease

    A transient defect in tyrosine metabolism is a common aminoacidopathy in the premature and full-term human infant. This disorder, termed neonatal tyrosinemia, was first described by Levine and Gordon in 1939. In the intervening years oth...

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
  2. Pathway

    Tyrosinemia, Transient, of the Newborn

    smpdb.ca/view/SMP0125592
    Disease

    A transient defect in tyrosine metabolism is a common aminoacidopathy in the premature and full-term human infant. This disorder, termed neonatal tyrosinemia, was first described by Levine and Gordon in 1939. In the intervening years oth...

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
  3. Pathway

    Alkaptonuria

    smpdb.ca/view/SMP0000169
    Disease

    Alkaptonuria (Homogentisic acid oxidase deficiency) is an autosomal recessive disease caused by a mutation in the HGD gene which codes for homogentisate 1,2-dioxygenase. A mutation in this enzyme results in accumulation of homogentisic a...

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
  4. Pathway

    Hawkinsinuria

    smpdb.ca/view/SMP0000190
    Disease

    Hawkinsinuria (4-Hydroxyphenylpyruvate Hydroxylase Deficiency) is an autosomal dominant disease caused by a mutation in the HPD gene which codes for 4-hydroxyphenylpyruvate dioxygenase. A deficiency in this enzyme results in accumulation...

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
  5. Pathway

    Tyrosinemia Type I

    smpdb.ca/view/SMP0125591
    Disease

    Tyrosinemia type I, also known as fumarylacetoacetase or FAH deficiency, is the most severe type of tyrosinemia, a buildup of tyrosine in the body. It is caused by an autosomal recessive mutation in the the FAH gene that encodes for fuma...

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
  6. Pathway

    Disulfiram Action Pathway

    smpdb.ca/view/SMP0000429
    Drug action

    Disulfiram inhibits dopamine beta-hydroxylase, which metabolizes dopamine into norepinephrine. This causes more dopamine to accumulate in the axon terminal and more dopamine is released.

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Adenosine phosphate · Tyrosine +27 more
  7. Pathway

    Alprenolol Action Pathway

    smpdb.ca/view/SMP0000297
    Drug action

    Blocking beta-1 adrenergic receptor could prevent the binding of epinephrine and norepinephrine, which could efficiently reduce blood pressure and heart rate.

    Drugs: ATP · Alprenolol · Potassium cation · Calcium
  8. Pathway

    Esmolol Action Pathway

    smpdb.ca/view/SMP0000301
    Drug action

    Normally, epinephrine and norepinephrine bind to the beta-1 adrenergic receptor with equal affinity and trigger a G-protein signalling cascade that result in the heart muscle contracting.

    Drugs: ATP · Esmolol · Potassium cation · Calcium
  9. Pathway

    Nadolol Action Pathway

    smpdb.ca/view/SMP0000303
    Drug action

    Nadolol bind to beta1-adrenergic receptors in heart and vascular smooth muscle to block the binding of other adrenergic neurotransmitters such as norepinephrine, which lead to decreased blood pressure,

    Drugs: ATP · Nadolol · Potassium cation · Calcium
  10. Pathway

    Oxprenolol Action Pathway

    smpdb.ca/view/SMP0000304
    Drug action

    Oxprenolol bind to beta1-adrenergic receptors in heart and vascular smooth muscle to block the binding of other adrenergic neurotransmitters such as norepinephrine, which lead to decreased blood pressure

    Drugs: ATP · Potassium cation · Calcium · Oxprenolol